Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

BACKGROUND AND AIMS: To assess the cost-effectiveness of utilizing IDegLira in comparison to other treatment regimens ( liraglutide and degludec) in managing type 2 diabetes, taking into account the Chinese healthcare system’s perspective. METHODS: The clinical data were obtained from the randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Ran, Wang, Weihao, Huang, Xiusheng, Qiao, Jingtao, Huang, Jinghe, Xing, Chang, Pan, Qi, Guo, Lixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439551/
https://www.ncbi.nlm.nih.gov/pubmed/37598203
http://dx.doi.org/10.1186/s13098-023-01141-7
_version_ 1785092970678059008
author Wei, Ran
Wang, Weihao
Huang, Xiusheng
Qiao, Jingtao
Huang, Jinghe
Xing, Chang
Pan, Qi
Guo, Lixin
author_facet Wei, Ran
Wang, Weihao
Huang, Xiusheng
Qiao, Jingtao
Huang, Jinghe
Xing, Chang
Pan, Qi
Guo, Lixin
author_sort Wei, Ran
collection PubMed
description BACKGROUND AND AIMS: To assess the cost-effectiveness of utilizing IDegLira in comparison to other treatment regimens ( liraglutide and degludec) in managing type 2 diabetes, taking into account the Chinese healthcare system’s perspective. METHODS: The clinical data were obtained from the randomized controlled trials (RCTs) of the DUAL I and DUAL II evidence studies that took place in China. To estimate the lifetime quality-adjusted life-years (QALYs) and direct medical costs of patients receiving different treatment strategies from a long-term perspective, the IQVIA CORE Diabetes Model version 9.0 (IQVIA, Basel, Switzerland) was utilized. The costs were evaluated from the perspective of the China National Health System. Future costs and clinical benefits were discounted annually at 5%, and sensitivity analyses were conducted. RESULTS: IDegLira was projected to reduce the incidence of diabetes-related complications and improve quality-adjusted life expectancy (QALE) versus liraglutide and degludec. A survival benefit was observed with IDegLira over Liraglutide (0.073 years). Lifetime costs were lower by Chinese yuan (CNY) 27,945 on IDegLira than on Liraglutide therapy. A similar survival benefit was observed with IDegLira over degludec (0.068 years). Lifetime costs were lower by CNY 1196 on IDegLira than on degludec therapy. Therefore, IDegLira was found to be cost-effective versus liraglutide and degludec with incremental cost-effectiveness ratios of Dominant per QALY gained, respectively, under the threshold of three times the gross domestic product (GDP) per capita in China. CONCLUSION: IDegLira is a cost-effective hypoglycemic treatment option that delivers positive clinical outcomes while also reducing costs for Chinese patients living with type 2 diabetes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-023-01141-7.
format Online
Article
Text
id pubmed-10439551
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-104395512023-08-20 Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients Wei, Ran Wang, Weihao Huang, Xiusheng Qiao, Jingtao Huang, Jinghe Xing, Chang Pan, Qi Guo, Lixin Diabetol Metab Syndr Research BACKGROUND AND AIMS: To assess the cost-effectiveness of utilizing IDegLira in comparison to other treatment regimens ( liraglutide and degludec) in managing type 2 diabetes, taking into account the Chinese healthcare system’s perspective. METHODS: The clinical data were obtained from the randomized controlled trials (RCTs) of the DUAL I and DUAL II evidence studies that took place in China. To estimate the lifetime quality-adjusted life-years (QALYs) and direct medical costs of patients receiving different treatment strategies from a long-term perspective, the IQVIA CORE Diabetes Model version 9.0 (IQVIA, Basel, Switzerland) was utilized. The costs were evaluated from the perspective of the China National Health System. Future costs and clinical benefits were discounted annually at 5%, and sensitivity analyses were conducted. RESULTS: IDegLira was projected to reduce the incidence of diabetes-related complications and improve quality-adjusted life expectancy (QALE) versus liraglutide and degludec. A survival benefit was observed with IDegLira over Liraglutide (0.073 years). Lifetime costs were lower by Chinese yuan (CNY) 27,945 on IDegLira than on Liraglutide therapy. A similar survival benefit was observed with IDegLira over degludec (0.068 years). Lifetime costs were lower by CNY 1196 on IDegLira than on degludec therapy. Therefore, IDegLira was found to be cost-effective versus liraglutide and degludec with incremental cost-effectiveness ratios of Dominant per QALY gained, respectively, under the threshold of three times the gross domestic product (GDP) per capita in China. CONCLUSION: IDegLira is a cost-effective hypoglycemic treatment option that delivers positive clinical outcomes while also reducing costs for Chinese patients living with type 2 diabetes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13098-023-01141-7. BioMed Central 2023-08-19 /pmc/articles/PMC10439551/ /pubmed/37598203 http://dx.doi.org/10.1186/s13098-023-01141-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wei, Ran
Wang, Weihao
Huang, Xiusheng
Qiao, Jingtao
Huang, Jinghe
Xing, Chang
Pan, Qi
Guo, Lixin
Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
title Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
title_full Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
title_fullStr Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
title_full_unstemmed Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
title_short Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients
title_sort evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (ideglira) versus other treatment regimens in the chinese type 2 diabetes patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439551/
https://www.ncbi.nlm.nih.gov/pubmed/37598203
http://dx.doi.org/10.1186/s13098-023-01141-7
work_keys_str_mv AT weiran evaluatingthelongtermcosteffectivenessoffixedratiocombinationinsulindegludecliraglutideidegliraversusothertreatmentregimensinthechinesetype2diabetespatients
AT wangweihao evaluatingthelongtermcosteffectivenessoffixedratiocombinationinsulindegludecliraglutideidegliraversusothertreatmentregimensinthechinesetype2diabetespatients
AT huangxiusheng evaluatingthelongtermcosteffectivenessoffixedratiocombinationinsulindegludecliraglutideidegliraversusothertreatmentregimensinthechinesetype2diabetespatients
AT qiaojingtao evaluatingthelongtermcosteffectivenessoffixedratiocombinationinsulindegludecliraglutideidegliraversusothertreatmentregimensinthechinesetype2diabetespatients
AT huangjinghe evaluatingthelongtermcosteffectivenessoffixedratiocombinationinsulindegludecliraglutideidegliraversusothertreatmentregimensinthechinesetype2diabetespatients
AT xingchang evaluatingthelongtermcosteffectivenessoffixedratiocombinationinsulindegludecliraglutideidegliraversusothertreatmentregimensinthechinesetype2diabetespatients
AT panqi evaluatingthelongtermcosteffectivenessoffixedratiocombinationinsulindegludecliraglutideidegliraversusothertreatmentregimensinthechinesetype2diabetespatients
AT guolixin evaluatingthelongtermcosteffectivenessoffixedratiocombinationinsulindegludecliraglutideidegliraversusothertreatmentregimensinthechinesetype2diabetespatients